PMV Pharmaceuticals, Inc. (PMVP)

2.3100 +0.0100 (+0.43%) At close: 04:00PM EST

PMV Pharmaceuticals, Inc.

8 Clarke Drive
Suite 3
Cranbury, NJ 08512
United States
609 642 6670
https://www.pmvpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 62

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David H. Mack Ph.D.	Co-Founder, CEO, President & Director	762.02k	N/A	1962
Dr. Arnold J. Levine Ph.D.	Co-Founder, Director & Member of Scientific Advisory Board	140k	N/A	1940
Mr. Winston Kung M.B.A.	COO & CFO	591.29k	N/A	1976
Dr. Leila Alland M.D.	Chief Medical Officer	601.93k	N/A	1963
Dr. Thomas E. Shenk Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1947
Mr. Robert Ticktin	General Counsel & Company Secretary	N/A	N/A	1962
Mr. Tim Smith	Senior VP & Head of Corporate Development	N/A	N/A	N/A
Ms. Crystal Zuckerman	Vice President of Human Resources	N/A	N/A	N/A
Dr. Binh Vu Ph.D.	Senior VP of Drug Discovery & CMC	N/A	N/A	N/A
Dr. Deepika Jalota Pharm.D.	Chief Development Officer	579.96k	87.59k	1977

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing Wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q, and R282W, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

Corporate governance

PMV Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.